- Home
- CWK vs TARS Comparison
CWK vs TARS Comparison
Compare CWK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | TARS |
|---|---|---|
| Founded | 1784 | 2016 |
| Country | United States | United States |
| Employees | 53000 | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CWK | TARS |
|---|---|---|
| Price | $13.42 | $59.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $17.64 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,288,200,000.00 | $451,360,000.00 |
| Revenue This Year | $6.87 | $56.43 |
| Revenue Next Year | $5.98 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.91 | ★ 146.71 |
| 52 Week Low | $11.57 | $39.79 |
| 52 Week High | $17.40 | $85.25 |
Technical Indicators
Market Signals| Indicator | CWK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 45.14 |
| Support Level | $13.56 | $56.05 |
| Resistance Level | $14.20 | $66.36 |
| Average True Range (ATR) | 0.59 | 2.65 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 73.06 | 56.66 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world and is headquartered in Chicago. The firm provides a broad suite of real estate-related services to owners, tenants, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.